Joshua R Huot
Overview
Explore the profile of Joshua R Huot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
329
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kim H, Huot J, Pin F, Belcher D, Bonetto A, Nader G
J Appl Physiol (1985)
. 2022 Oct;
133(6):1273-1283.
PMID: 36201323
We investigated the impact of tumor burden on muscle wasting in metastatic (m) and xenograft (x) models of colorectal cancer (CRC). Male Nod SCID γ and CD2F1 mice were injected...
12.
Essex A, Deosthale P, Huot J, Davis H, Momeni N, Bonetto A, et al.
Biol Sex Differ
. 2022 Oct;
13(1):56.
PMID: 36183096
Background: Osteocytic microRNA21 (miR21) removal alters cytokine production and bone mass by modulating osteoclast and osteoblast differentiation and activity. Removing osteocytic miR21 increases osteoclast/osteoblast numbers and bone mass in male...
13.
Huot J, Pin F, Chatterjee R, Bonetto A
J Cachexia Sarcopenia Muscle
. 2022 Jul;
13(5):2480-2491.
PMID: 35903870
Background: Chemotherapy induces a cachectic-like phenotype, accompanied by skeletal muscle wasting, weakness and mitochondrial dysfunction. Peroxisome proliferator-activated receptor-gamma coactivator-1 alpha (PGC1α), a regulator of mitochondrial biogenesis, is often reduced in...
14.
Essex A, Huot J, Deosthale P, Wagner A, Figueras J, Davis A, et al.
J Bone Miner Res
. 2022 May;
37(7):1366-1381.
PMID: 35575023
Previous studies proposed the Triggering Receptor Expressed on Myeloid Cells 2 (TREM2), a receptor expressed in myeloid cells including microglia in brain and osteoclasts in bone, as a link between...
15.
Huot J, Pin F, Bonetto A
Am J Cancer Res
. 2022 Apr;
12(3):1435.
PMID: 35411220
[This corrects the article on p. 2990 in vol. 11, PMID: 34249440.].
16.
Pin F, Huot J, Bonetto A
Front Cell Dev Biol
. 2022 Apr;
10:861622.
PMID: 35392166
Cancer cachexia is a debilitating syndrome characterized by skeletal muscle wasting, weakness and fatigue. Several pathogenetic mechanisms can contribute to these muscle derangements. Mitochondrial alterations, altered metabolism and increased oxidative...
17.
Pin F, Jones A, Huot J, Narasimhan A, Zimmers T, Bonewald L, et al.
J Bone Miner Res
. 2021 Dec;
37(3):381-396.
PMID: 34904285
Tumor- and bone-derived soluble factors have been proposed to participate in the alterations of skeletal muscle size and function in cachexia. We previously showed that mice bearing ovarian cancer (OvCa)...
18.
Gerrard J, Hay J, Adams R, Williams 3rd J, Huot J, Weathers K, et al.
Int J Environ Res Public Health
. 2021 Dec;
18(23).
PMID: 34886282
The evolutionarily conserved signaling pathway Notch is unequivocally essential for embryogenesis. Notch's contribution to the muscle repair process in adult tissue is complex and obscure but necessary. Notch integrates with...
19.
Huot J, Thompson B, McMullen C, Marino J, Arthur S
Cells
. 2021 Aug;
10(7).
PMID: 34359954
It has been demonstrated that inhibiting Notch signaling through γ-secretase inhibitor (GSI) treatment increases myogenesis, AKT/mTOR signaling, and muscle protein synthesis (MPS) in C2C12 myotubes. The purpose of this study...
20.
Muscle weakness caused by cancer and chemotherapy is associated with loss of motor unit connectivity
Huot J, Pin F, Bonetto A
Am J Cancer Res
. 2021 Jul;
11(6):2990-3001.
PMID: 34249440
Skeletal muscle wasting and weakness caused by cancer and its treatments (known as "cachexia") drastically impair quality of life and worsen survival outcomes in cancer patients. There are currently no...